Yale Center for Asthma and Airway Diseases Now Enrolling COPD Trial

February 23, 2020

The Yale Center for Asthma and Airway Diseases (YCAAD) is now enrolling patients for a randomized, double-blind, placebo-controlled, parallel group, multicenter Phase 2a Study to explore the efficacy and safety of Tezepelumab (anti-TSLP) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) (COURSE).

Please see the flyer below for all pertinent information.

Featured in this article

Angela Nunez
Research Associate 3
Lauren Cohn, MD
Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine); Associate Director, MD/PHD Program; Director, Newington VA Pulmonary Clinic, Medicine, VA Connecticut Health System
Geoffrey Chupp, MD
Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine ); Director, Yale Center for Asthma and Airways Disease (YCAAD), Pulmonary, Critical Care & Sleep Medicine; Director, Pulmonary Function Laboratory, Yale-New Haven Hospital, Pulmonary, Critical Care & Sleep Medicine